Back to Search Start Over

Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19

Authors :
Ramos-Rincón, Jose Manuel
Pérez-Belmonte, Luis M
Carrasco-Sánchez, Francisco Javier
Jansen-Chaparro, Sergio
De-Sousa-Baena, Mercedes
Bueno-Fonseca, José
Pérez-Aguilar, Maria
Arévalo-Cañas, Coral
Bacete Cebrian, Marta
Méndez-Bailón, Manuel
Fiteni Mera, Isabel
González García, Andrés
Navarro Romero, Francisco
Tuñón de Almeida, Carlota
Muñiz Nicolás, Gemma
González Noya, Amara
Hernández Milian, Almudena
García García, Gema María
Alcalá Pedrajas, José Nicolás
Herrero García, Virginia
Corral-Gudino, Luis
Comas Casanova, Pere
Meijide Míguez, Héctor
Casas-Rojo, José Manuel
Gómez-Huelgas, Ricardo
SEMI-COVID-19 Network
Source :
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante, instname, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
Publication Year :
2021
Publisher :
Oxford University Press, 2021.

Abstract

Background The effects of cardiometabolic drugs on the prognosis of diabetic patients with COVID-19, especially very old patients, are not well known. This work was aimed to analyze the association between preadmission cardiometabolic therapy (antidiabetic, antiaggregant, antihypertensive, and lipid-lowering drugs) and in-hospital mortality among patients ≥80 years with type 2 diabetes mellitus (T2DM) hospitalized for COVID-19. Method We conducted a nationwide, multicenter, observational study in patients ≥80 years with T2DM hospitalized for COVID-19 between March 1 and May 29, 2020. The primary outcome measure was in-hospital mortality. A multivariate logistic regression analysis was performed to assess the association between preadmission cardiometabolic therapy and in-hospital mortality. Results Of the 2 763 patients ≥80 years old hospitalized due to COVID-19, 790 (28.6%) had T2DM. Of these patients, 385 (48.7%) died during admission. On the multivariate analysis, the use of dipeptidyl peptidase-4 inhibitors (adjusted odds ratio [AOR] 0.502, 95% confidence interval [CI]: 0.309–0.815, p = .005) and angiotensin receptor blockers (AOR 0.454, 95% CI: 0.274–0.759, p = .003) were independent protectors against in-hospital mortality, whereas the use of acetylsalicylic acid was associated with higher in-hospital mortality (AOR 1.761, 95% CI: 1.092–2.842, p = .020). Other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins showed neutral association with in-hospital mortality. Conclusions We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with T2DM hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers could reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins seem to have a neutral effect; and acetylsalicylic acid could be associated with excess mortality.

Details

ISSN :
10795006
Database :
OpenAIRE
Journal :
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante, instname, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
Accession number :
edsair.doi.dedup.....609e7b999c26dd329fbdaebaa3447cbf